Supernus Pharmaceuticals, Inc. (SUPN) has a negative trailing P/E of -75.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 26.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -1.32%, forward earnings yield 3.83%. PEG 0.68 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 69/100 with 5/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 13.7 | 0.03 | 6.51 | 5.81 | - |
| 2017 | 35.3 | -0.92 | 7.56 | 6.69 | - |
| 2018 | 15.6 | 0.18 | 3.81 | 4.22 | - |
| 2019 | 11.0 | 7.81 | 2.09 | 3.17 | - |
| 2020 | 10.4 | 0.90 | 1.78 | 2.54 | - |
| 2021 | 29.0 | -0.50 | 1.90 | 2.67 | - |
| 2022 | 31.5 | 2.65 | 2.16 | 2.87 | - |
| 2023 | 1,199.3 | -12.25 | 1.71 | 2.60 | - |
| 2024 | 27.0 | 0.00 | 1.92 | 3.01 | - |
| 2025 | -72.8 | 0.48 | 2.64 | 3.90 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $1.76 | $215M | $91.22M | 42.4% |
| 2017 | $1.08 | $302.24M | $57.28M | 19% |
| 2018 | $2.05 | $408.9M | $110.99M | 27.1% |
| 2019 | $2.10 | $392.76M | $113.06M | 28.8% |
| 2020 | $2.36 | $520.4M | $126.95M | 24.4% |
| 2021 | $0.98 | $579.78M | $53.42M | 9.2% |
| 2022 | $1.04 | $667.24M | $60.71M | 9.1% |
| 2023 | $0.02 | $607.52M | $1.32M | 0.2% |
| 2024 | $1.32 | $661.82M | $73.87M | 11.2% |
| 2025 | $-0.68 | $718.95M | $-38.55M | -5.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $1.92 | $1.69 – $2.15 | $865.01M | $860.8M – $869.21M | 1 |
| 2027 | $3.52 | $3.21 – $3.84 | $1.02B | $991.88M – $1.04B | 1 |
| 2028 | $5.19 | $2.33 – $8.05 | $1.16B | $1.13B – $1.19B | 2 |
| 2029 | $6.91 | $6.67 – $7.08 | $1.31B | $1.27B – $1.33B | 1 |
| 2030 | $7.01 | $6.77 – $7.19 | $1.37B | $1.33B – $1.4B | 1 |
